Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

BACKGROUND: This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer. METHODS: Previously untreated patients with wild-type KRAS t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez-Plana, Julen, Pericay, Carlos, Quintero, Guillermo, Alonso, Vicente, Salud, Antonieta, Mendez, Miguel, Salgado, Mercedes, Saigi, Eugeni, Cirera, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251687/
https://www.ncbi.nlm.nih.gov/pubmed/25417182
http://dx.doi.org/10.1186/1471-2407-14-865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251687/
https://www.ncbi.nlm.nih.gov/pubmed/25417182
http://dx.doi.org/10.1186/1471-2407-14-865

Ejemplares similares